Corsera develops predictive solutions aimed at preventing cardiovascular disease before onset. The company leverages advanced science and AI technology to redefine cardiovascular wellness. This approach empowers individuals to achieve longer, healthier lives through proactive health management.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiovascular disease remains the leading cause of mortality globally, with current medical practices often intervening only after significant arterial damage has occurred. This reactive approach fails to adequately address the cumulative exposure to risk factors like hypertension and elevated cholesterol, leading to irreversible injury and increased risk of cardiac events.
Solution
Corsera Health is developing a proactive approach to cardiovascular health by integrating predictive analytics with novel RNA interference (RNAi) therapeutics. Their proprietary Klotho Health tool utilizes causal AI to assess an individual's lifetime risk of cardiovascular disease and quantify the potential benefits of early intervention. This predictive capability is paired with a once-annual subcutaneous RNAi medicine designed to reduce key disease drivers, such as PCSK9 and angiotensinogen. The aim is to shift the paradigm from late-stage disease management to early prevention, thereby extending cardiovascular healthspan and reducing morbidity and mortality.
Target Audience
The primary target audience includes individuals at risk for cardiovascular disease, healthcare providers seeking advanced predictive and preventive tools, and pharmaceutical partners interested in novel RNAi therapeutics.
Features
- Klotho Health: A proprietary, AI-enabled precision health tool for predicting lifetime cardiovascular disease risk and quantifying healthspan extension opportunities.
- Preventive RNAi Medicine: A dual-targeting siRNA therapeutic designed for once-annual subcutaneous administration to reduce PCSK9 and AGT levels.
- Causal AI Integration: Leverages causal artificial intelligence to understand and model cause-and-effect relationships in cardiovascular disease progression.
- RNA Interference (RNAi) Technology: Utilizes siRNA molecules to specifically silence disease-driving genes, preventing the production of harmful proteins.
- Scalable Manufacturing and Clinical Trial Approach: Focuses on efficient global clinical trials and partnerships with manufacturing organizations for broad market supply.
- Early Intervention Strategy: Targets risk factors like high blood pressure and LDL cholesterol before irreversible arterial damage occurs.